Javier Castro-Carpeño

Publications (2)4.07 Total impact

• Article: Serum interleukin-15 levels in cancer patients with cachexia.

  Pedro L Martínez-Hernández, Angel Hernanz-Macías, Carmen Gómez-Candela, Cristina Grande-Aragón, Jaime Feliu-Batlle, Javier Castro-Carpeño, Isabel Martínez-Muñoz, Laura Zurita-Rosa, Marta Villarino-Sanz, Concepción Prados-Sánchez, Joaquín Sánchez García-Girón
  [show abstract] [hide abstract]
  ABSTRACT: Interleukin-15 (IL-15) has important anabolic effects on muscle protein metabolism through a decrease in the ATP-ubiquitin-dependent proteolytic pathway. The role of IL-15 in human cancer cachexia is unknown. The aim of this study was to assess the relationship between interleukin-15 (IL-15) in cancer patients with cachexia at diagnosis of malignancy and 8 weeks later. An observational study of 21 cancer patients (with and without cachexia) and 8 healthy subjects was conducted. Body composition was measured by leg-to-leg impedance. Serum IL-15 levels were assessed at baseline and after 4 and 8 weeks. Baseline IL-15 values were similar in cancer patients and in healthy subjects. Cancer patients with lower baseline levels of IL-15 (<2 pg/ml) had significantly higher fat mass (%) along the study. Eighteen patients completed the study: five patients showed an increase of 3.7 kg at the end of the study (5.4% of body weight) and showed a mean increase of IL-15 of 1.32 pg/ml (121%) at 4 weeks and 2.32 pg/ml (197%) at 8 weeks, as compared with mean decrease of -4.1 kg (-5.3%) and -0.09 pg/ml (-2.5%) and 0.6 pg/ml (40.8%) in the 13 patients who lost weight (P=0.001 and P=0.022, respectively). Changes of IL-15 at 4 and 8 weeks were directly associated with changes in body weight, body mass index (BMI), fat-free mass and muscle mass (P<0.05), and indirectly associated with percentage of weight loss (P<0.05). In summary, although the results indicate that IL-15 does not have a role in cancer cachexia pathogenesis, the association during evolution between serum IL-15 and changes in weight and muscle mass suggests a possible role of IL-15 as a marker of the body composition response in cancer patients who are losing weight at the time of diagnosis.
  Oncology Reports 07/2012; 28(4):1443-52. · 1.84 Impact Factor
• Article: WITHDRAWN:Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases.

  Javier de Castro-Carpeño, María Sereno Moyano, Enrique Casado Sáenz, Cristóbal Belda-Iniesta, Jaime Feliu Batlle, Manuel González Barón
  [show abstract] [hide abstract]
  ABSTRACT: withdrawn by publisher: Bevacizumab has been shown to be effective combined with chemotherapy for first-line treatment of advanced colorectal cancer, but little information is available about its efficacy and safety in patients who may be candidates for surgery at any time during the disease. The case history of a female patient with colorectal cancer, undergoing surgery for liver metastases and bilateral surgery for lung metastases at different time-points during her disease, is reported. Perioperative bevacizumab administration caused no complications either associated with surgery, in the early postoperative period, or in the subsequent months.
  Anti-cancer drugs 05/2009; 20 Special Issue 1:S7-S10. · 2.23 Impact Factor